Standard
Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers. / Rohrberg, Kristoffer S; Olesen, René K; Pfeiffer, Per; Ladekarl, Morten; Pappot, Helle; Christensen, Ib J; Høyer-Hansen, Gunilla; Sørensen, Morten; Skov, Birgit G; Buysschaert, Ian; Carmeliet, Peter; Lassen, Ulrik.
I:
Acta oncologica (Stockholm, Sweden), Bind 51, Nr. 2, 02.2012, s. 234-42.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
Rohrberg, KS, Olesen, RK, Pfeiffer, P, Ladekarl, M
, Pappot, H, Christensen, IJ, Høyer-Hansen, G, Sørensen, M, Skov, BG, Buysschaert, I, Carmeliet, P
& Lassen, U 2012, '
Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers',
Acta oncologica (Stockholm, Sweden), bind 51, nr. 2, s. 234-42.
https://doi.org/10.3109/0284186X.2011.619568APA
Rohrberg, K. S., Olesen, R. K., Pfeiffer, P., Ladekarl, M.
, Pappot, H., Christensen, I. J., Høyer-Hansen, G., Sørensen, M., Skov, B. G., Buysschaert, I., Carmeliet, P.
, & Lassen, U. (2012).
Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers.
Acta oncologica (Stockholm, Sweden),
51(2), 234-42.
https://doi.org/10.3109/0284186X.2011.619568Vancouver
Rohrberg KS, Olesen RK, Pfeiffer P, Ladekarl M
, Pappot H, Christensen IJ o.a.
Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers.
Acta oncologica (Stockholm, Sweden). 2012 feb.;51(2):234-42.
https://doi.org/10.3109/0284186X.2011.619568Author
Rohrberg, Kristoffer S ; Olesen, René K ; Pfeiffer, Per ; Ladekarl, Morten ; Pappot, Helle ; Christensen, Ib J ; Høyer-Hansen, Gunilla ; Sørensen, Morten ; Skov, Birgit G ; Buysschaert, Ian ; Carmeliet, Peter ; Lassen, Ulrik. / Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers. I: Acta oncologica (Stockholm, Sweden). 2012 ; Bind 51, Nr. 2. s. 234-42.
Bibtex
@article{730a3b3285ba4e7e93f49bf1da1de60f,
title = "Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers",
abstract = "Patients with upper gastrointestinal cancers have a poor prognosis and only few treatment options. The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are valid targets in many solid tumours, and they have synergistic effects in preclinical studies.",
keywords = "Adult, Aged, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Carcinoma, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Resistance, Neoplasm, Drug Therapy, Combination, Female, Follow-Up Studies, Gastrointestinal Neoplasms, Humans, Male, Middle Aged, Prospective Studies, Quinazolines, Receptor, Epidermal Growth Factor, Survival Analysis, Treatment Outcome",
author = "Rohrberg, {Kristoffer S} and Olesen, {Ren{\'e} K} and Per Pfeiffer and Morten Ladekarl and Helle Pappot and Christensen, {Ib J} and Gunilla H{\o}yer-Hansen and Morten S{\o}rensen and Skov, {Birgit G} and Ian Buysschaert and Peter Carmeliet and Ulrik Lassen",
year = "2012",
month = feb,
doi = "10.3109/0284186X.2011.619568",
language = "English",
volume = "51",
pages = "234--42",
journal = "Acta Odontologica Scandinavica",
issn = "0001-6357",
publisher = "Taylor & Francis",
number = "2",
}
RIS
TY - JOUR
T1 - Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers
AU - Rohrberg, Kristoffer S
AU - Olesen, René K
AU - Pfeiffer, Per
AU - Ladekarl, Morten
AU - Pappot, Helle
AU - Christensen, Ib J
AU - Høyer-Hansen, Gunilla
AU - Sørensen, Morten
AU - Skov, Birgit G
AU - Buysschaert, Ian
AU - Carmeliet, Peter
AU - Lassen, Ulrik
PY - 2012/2
Y1 - 2012/2
N2 - Patients with upper gastrointestinal cancers have a poor prognosis and only few treatment options. The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are valid targets in many solid tumours, and they have synergistic effects in preclinical studies.
AB - Patients with upper gastrointestinal cancers have a poor prognosis and only few treatment options. The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are valid targets in many solid tumours, and they have synergistic effects in preclinical studies.
KW - Adult
KW - Aged
KW - Angiogenesis Inhibitors
KW - Antibodies, Monoclonal, Humanized
KW - Carcinoma
KW - Disease-Free Survival
KW - Dose-Response Relationship, Drug
KW - Drug Resistance, Neoplasm
KW - Drug Therapy, Combination
KW - Female
KW - Follow-Up Studies
KW - Gastrointestinal Neoplasms
KW - Humans
KW - Male
KW - Middle Aged
KW - Prospective Studies
KW - Quinazolines
KW - Receptor, Epidermal Growth Factor
KW - Survival Analysis
KW - Treatment Outcome
U2 - 10.3109/0284186X.2011.619568
DO - 10.3109/0284186X.2011.619568
M3 - Journal article
C2 - 22017239
VL - 51
SP - 234
EP - 242
JO - Acta Odontologica Scandinavica
JF - Acta Odontologica Scandinavica
SN - 0001-6357
IS - 2
ER -
